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Abstract
Background The identification of new hereditary breast cancer genes is an area of highly active research. In 2015, two inde-
pendent studies provided initial evidence for a novel breast cancer susceptibility gene, RECQL, a DNA helicase which plays 
an important role in the DNA damage response. Several subsequent studies in independent patient cohorts have provided 
further data on RECQL variant frequency in additional populations, some of which have brought in to question the increased 
breast cancer risk associated with RECQL mutations.
Results The initial reports present findings from whole exome sequencing of high-risk familial breast cancer cases in the 
French-Canadian, Polish and Han Chinese populations and estimate the carrier frequency of pathogenic RECQL mutations 
in high-risk breast cancer patients who have previously tested negative for BRCA1 and BRCA2 mutations to be approximately 
1–2%. Proposed founder mutations were identified in French-Canadian and Polish populations. Functional studies support 
loss of function of the helicase activity of RECQL for some of the reported pathogenic mutations. An additional study in a 
cohort of Southern Chinese high-risk breast cancer patients estimated the frequency of pathogenic RECQL mutations to be 
0.54%. A possible Chinese founder mutation was identified, but only a small number of controls were sequenced. Subsequent 
case–control studies screening for the Polish founder mutation in patients from Germany and Belarus did not find any evi-
dence for increased breast cancer risk for this variant. An Australian case–control study also failed to identify an increased 
risk of breast cancer associated with RECQL loss of function variants.
Conclusions RECQL plays an important role in DNA repair, and is a plausible candidate breast cancer susceptibility gene. 
Initial studies showed evidence of an association between variants in this gene and an increased breast cancer risk in three 
separate populations, and identified founder mutations with significantly increased odds ratios. However, several subsequent 
studies have failed to support the association. With the limited and conflicting evidence available, there remains debate as 
to whether there is an increased breast cancer risk in individuals carrying RECQL loss of function variants. Further studies 
are required to better quantify the risks associated with RECQL variants and the current evidence base is not sufficient to 
justify routine inclusion of RECQL on breast cancer gene panels in clinical use. Management of patients in whom RECQL 
variants have been identified should be based on clinician assessment, in the context of the family history. Further studies are 
required to better quantify the risks to RECQL mutation carriers and may also guide management and potential therapeutic 
targeting for patients.
Keywords Breast cancer · Gene panel testing · Topoisomerase inhibition · RECQ · Cancer predispostion
Introduction
RECQL (also known as RECQL1 and RECQ1) is located on 
chromosome 12p12 and encodes a DNA helicase. It belongs 
to a class of DExH-containing helicases which have impor-
tant functions in DNA repair, replication, recombination 
and transcription. In particular, the importance of RECQL 
has been identified in DNA double-strand break repair. 
The observation that genes encoding other components of 
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this network are known to act as breast cancer susceptibil-
ity genes pointed towards the significance of RECQL as a 
potential breast cancer susceptibility gene.
In 2015, two independent research groups who used dif-
ferent screening strategies to search for new cancer predispo-
sition genes, published evidence suggesting that RECQL is 
a novel breast cancer susceptibility gene. Cybulski et al. [1] 
used whole exome data from patients with high-risk heredi-
tary breast cancer in two distinct populations, Polish and 
French-Canadian, both known to harbour founder mutations 
in other hereditary breast cancer genes. Sun et al. [2] used 
whole exome sequencing in a much smaller cohort of early 
onset breast cancer patients derived from the Han Chinese 
population. Both groups went on to perform validation in a 
broader patient group.
Following these initial studies, further papers were pub-
lished investigating the frequency of RECQL variants in 
additional breast cancer patient populations. Kwong et al. [3] 
screened a cohort of breast cancer patients of Southern Chi-
nese origin for RECQL variants by targeted sequencing of all 
coding exons. Nguyen-Dumont et al. [4] used a similar strat-
egy to screen breast and ovarian cancer patients from Poland 
and Ukraine. Li et al. [5] performed similar screening in a 
cohort of Australian patients with a family history of breast 
cancer and a personal history of breast (> 95%) or ovar-
ian cancer. Li et al. additionally sequenced a large control 
population. Other screening strategies included searching for 
rare RECQL missense variants, predicted to be deleterious, 
as performed by Tervasmäki et al. [6] in a cohort of Finn-
ish breast cancer patients and controls. Bogdanova et al. [7] 
screened two separate breast cancer case–control series, one 
from Belarus, the other from Germany, only for the putative 
Polish founder mutation (c.1667_1667 + 3delAGTA) identi-
fied by Cybulski et al. Table 1 summarises the methodology 
and variant frequencies across the key studies.
Results
Prevalence of mutations
In their discovery phase, Cybulski et al. used whole exome 
data from 195 patients who had previously tested negative 
for founder mutations in other key breast cancer suscepti-
bility genes (BRCA1, BRCA2, CHEK2, NBN and PALB2). 
They identified five patients carrying truncating RECQL 
mutations (2.6%) compared to 8/4300 (0.2%) in their con-
trol cohort (p = 2.0 × 10−4). They also identified four patients 
carrying missense variants with a mean allele frequency 
(MAF) < 1%, although no functional data to determine the 
pathogenicity of these variants were reported. In the valida-
tion phase, two further truncating mutations (both of which 
were identified as founder mutations—see below), and 
twelve missense variants were identified.
Using their initial study population of nine high-risk 
breast cancer patients, who had previously tested nega-
tive for BRCA1 and BRCA2 mutations, Sun et al. identified 
RECQL mutations in two patients, prompting them to further 
investigate the gene. Subsequent screening of RECQL in 
439 familial breast cancer patients (who had tested negative 
for BRCA1 and BRCA2 mutations) found nine patients with 
putative pathogenic mutations (three nonsense, one splice 
site and five missense mutations predicted to be pathogenic) 
giving an overall frequency of 2.0% (0.9% if missense vari-
ants are excluded). Only one plausibly pathogenic missense 
mutation was found in 1588 controls (p = 9.14 × 10−6).
Kwong et  al. screened 1110 breast cancer patients 
recruited through the Hong Kong Hereditary and High-Risk 
Breast Cancer Program who had previously tested negative 
for BRCA1, BRCA2, TP53 and PTEN mutations. They iden-
tified four predicted pathogenic mutations in six patients 
(one frame-shift deletion, two splice site variants and one 
nonsense variant). Additionally, 14 missense variants were 
detected; two missense mutations in the RQC domain, iden-
tified in three patients, were predicted to be pathogenic by 
SIFT and PolyPhen, but no functional investigations were 
reported. Kwong et al. calculated the overall pathogenic 
mutation frequency in their cohort as 0.54% (6/1110), 
excluding the missense variants. No predicted pathogenic 
mutations were identified in the 88 controls tested.
Nguyen-Dumont et al. screened 338 breast cancer patients 
and 89 ovarian cancer patients and did not identify any loss 
of function RECQL variants. One predicted pathogenic mis-
sense variant was identified. No control samples were tested. 
Li et al. screened 4536 women who had previously had a 
negative result from BRCA1 and BRCA2 mutation testing, 
had a family history of breast cancer and a personal his-
tory of breast cancer (> 95%) or ovarian cancer. They also 
screened 4576 cancer-free female controls. Thirteen loss-of-
function variants were detected in cases (0.29%), compared 
to 25 loss-of-function variants in controls (0.55%). The dif-
ference between cases and controls was not significantly dif-
ferent [Odds ratio (OR) 0.52, 95% CI 0.25–1.06, p = 0.072]. 
Rare missense variants with a minor allele frequency ≤ 0.5% 
were detected in 54 cases (1.19%) and 37 controls (0.81%), 
p = 0.073, and there remained no statistically significant 
difference when the variants were filtered for pathogenicity 
using in silico tools. Notably, a single truncating mutation, 
c.1859C>G (p.Ser620*) was the most common mutation 
in both cases (6/13) and controls (16/25) in the Australian 
study. This mutation is seen at a frequency of 0.20% in the 
Exome Aggregation Consortium (ExAC) European dataset, 
although data are present for only a subset of ExAC partic-
pants [8]. Cybulski et al. removed this variant from their 
analysis of population level data, stating that as the variant 
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falls in the last exon on the protein it is ‘not expected to be 
deleterious to RECQL protein function’.
Taken together, these studies show frequencies of RECQL 
loss of function variants of 0–2.6% in patients with high-risk 
familial breast cancer who have previously tested negative 
for mutations in BRCA1/BRCA2 and other hereditary breast 
cancer genes. The frequency of loss of function variants in 
the control cohorts of these studies range from 0 to 0.55%.
Founder mutations
The data analysed by Cybulski et  al. was specifically 
selected from populations known to harbour founder muta-
tions. The identification of founder mutations in both the 
French-Canadian and Polish populations was an outcome 
of the validation phase of the study. One recurrent trun-
cating mutation: c.643C > T (p.Arg215) was identified 
in the French-Canadian population in 7/1013 (0.69%) 
high-risk breast cancer patients compared to 1/7136 
(0.014%) controls (p = 3.0 × 10− 6). The founder muta-
tion in the Polish population: c.1667_1667 + 3delAGTA 
(p.K555delinsMYKLIHYSFR), was seen in 30/13136 
(0.23%) breast cancer cases and 2/4702 (0.04%) cancer-free 
controls (p = 0.008).
Further data on the Polish founder mutation identified 
by Cybulski et al. were provided by Bogdanova et al. who 
undertook c.1667_1667 + 3delAGTA mutation analysis in 
two breast cancer case–control series from Belarus and Ger-
many. In the Belarus cohort of 1475 breast cancer patients 
and 1202 healthy controls, the mutation was identified in 
five cases (0.34%) and four controls (0.33%). In the Ger-
man cohort of 1121 breast cancer patients and 930 healthy 
controls, the mutation was identified in four cases (0.36%) 
and two controls (0.22%). Combined analysis of these two 
case–control series did not confirm the association of this 
RECQL mutation with a significantly increased risk of breast 
cancer (Mantel–Haenszel OR 1.23, 95% CI 0.44–3.47; 
p = 0.69). Although the frequency of the mutation in breast 
cancer cases is similar to that seen in the study from Cybul-
ski et al., the frequency of the mutation in the control popu-
lations is much higher (0.2–0.3% vs. 0.04%, p = 0.01). By 
comparison, frequency of this mutation in the ExAC non-
Finnish European dataset is 0.06%. This mutation was not 
identified by Nguyen-Dumont et al. in any of the 304 Polish 
or 123 Ukrainian patients in their cohort.
The possibility of a Chinese RECQL founder mutation 
was raised by Kwong et al. who identified two patients car-
rying the c.796C > T (p.Gln266*) variant, which was also 
detected in one patient in the earlier study by Sun et al. This 
variant was also detected by Li et al. in one control subject 
in their Australian cohort, but was not detected in any cancer 
patients in their study. Notably, this variant is also present 
in five individuals of East Asian origin in the ExAC dataset, Ta
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giving frequency of 0.06% in this population. Tervasmäki 
et al. suggest a possible Finnish RECQL founder mutation, 
identified by their search for rare RECQL missense vari-
ants. In a cohort of 1946 breast cancer cases, they observed 
six carriers of the missense variant c.468T > G (p.I156M) 
(0.3%), which was not identified in any of the 1408 controls 
tested, giving a borderline significance (p = 0.043).
Penetrance of breast cancer
None of the studies comment on the penetrance of breast 
cancer associated with RECQL mutations, but information 
can be drawn from the odds ratios (OR) presented [9]. Li 
et al. do not report a significantly increased risk of breast 
cancer in their analysis of all loss of function mutations 
in the Australian case–control cohort. (OR 0.52, 95% CI 
0.25–1.06; p = 0.072). However, Cybulski et al. report an 
odds ratio of 5.4 for the Polish founder mutation data, with 
very wide 95% confidence intervals (1.3–46). Data from 
Bogdanova et al. taken alone, does not show a significantly 
increased risk of breast cancer associated with the Pol-
ish founder mutation (Mantel–Haenszel OR 1.23, 95% CI 
0.44–3.47; p = 0.69), but a meta-analysis combining their 
data with data from Cybulski et al. gives an overall odds 
ratio of 2.51 (95% CI 1.13–5.57; p = 0.02). These data relate 
only to the c.1667_1667 + 3delAGTA mutation, which is 
a splicing mutation, predicted to result in insertion of 27 
nucleotides disrupting a crucial hairpin sequence. These data 
suggest the possibility that the Polish founder mutation is 
associated with an increased breast cancer risk, and it could 
be that breast cancer risks associated with RECQL mutations 
are highly variant specific. More data are needed to confirm 
whether the Polish founder mutation is associated with an 
increased breast cancer risk and determine the risks associ-
ated with other mutations.
Range of cancer sites implicated
Cybulski et al. report that two RECQL truncating muta-
tion carriers (not carriers of the putative founder mutation) 
had a positive family history of ovarian cancer. Tervasmäki 
et al. report a family history of ovarian cancer in three of 
the six patients carrying the p.I156M missense variant, and 
pancreatic cancer in two families. Sun et al. provide further 
information on a single family in which a RECQL splic-
ing mutation 395-2A > G was identified. Twelve individu-
als in this pedigree were affected with cancer: seven breast, 
one ovarian, one peritoneal, one cervical, one lung and 
one malignancy of uncertain origin. In the second Chinese 
cohort of mutation carriers, Kwong et al. report one patient 
with a family history of prostate and colon cancer, and two 
patients with a family history of liver cancer. No clear pat-
tern of additional associated cancer sites is apparent from 
currently available data on RECQL mutation carriers and 
associated family history.
Determining the pathogenicity of variants
The plausible role of RECQL as a pathogenic gene was 
theorised by all groups. RECQL is one of the five RECQ 
genes, three of which (BLM, WRN and RECQL4) have 
been implicated in genetic disorders with increased can-
cer risk [10–12]. It has also been proposed that variants in 
RECQL5 are associated with increased breast cancer risk in 
the Chinese population [13]. However, prior to the poten-
tial association with breast cancer susceptibility, mutations 
in RECQL had not previously been reported in any human 
genetic disorders.
RECQL is involved in double strand break repair and 
plays an important role in the maintenance of genomic sta-
bility. RECQL prevents dsDNA breaks by stabilising stalled 
or regressed replications forks [14]. It is involved in non-
homologous end joining [15] and lengthening of telom-
eres without telomerase [16]. The protein product contains 
two important domains: the helicase domain and the RecQ 
carboxy-terminal domain. Both are highly conserved in the 
RECQ family and are important for helicase activity.
In vitro work on RECQL has been carried out in both 
mouse and human cell lines. Primary embryonic fibroblasts 
from RECQL-knock down mice showed aneuploidy, spon-
taneous and frequent chromosomal breakage and transloca-
tions [17]. Mouse and human RECQL-depleted cells display 
high rate of spontaneous sister chromatid exchange and are 
more sensitive to ionising radiation [18].
Ahmed et al. argue that observed differences in breast 
cancer risk between studies may be due to the fact that only 
certain variants are pathogenic [19]. In terms of specific 
variants, Cybulski et al. provide in silico data to predict 
the pathogenicity of the recurrent Polish mutation that they 
identified. This in-frame indel displaces residues 558–566 
which form a beta hairpin in the secondary structure of the 
RECQL protein. This structural hairpin functions as a DNA 
strand separator and is likely to be critical to the protein’s 
function in unwinding the replication fork [20]. Tervasmäki 
et al. hypothesise the pathogenicity of the p.I156M missense 
variant based on evolutionary conservation of this region, 
and localisation to the ATPase domain.
Sun et al. provide a more detailed analysis of some of 
their variants. Fifteen variants were identified in their final 
cohort of 448 patients (three nonsense, two potential splice 
site and ten missense mutations). Three missense variants 
were also identified in the control population and two were 
presumed not to be pathogenic due to their similar frequency 
in cases and controls. In vitro functional studies using GST 
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fusion proteins showed that five out of eight missense vari-
ants significantly disrupted helicase activity. Splice site 
analyses by RT-PCR provided evidence of potential patho-
genicity for only one of the two splice site variants. All three 
nonsense mutations were found to lie within the helicase 
domain, and their effect of premature protein termination 
resulting in loss of helicase activity led the authors to class 
them as pathogenic variants, although the functional data to 
support this is not presented. Sun et al. conclude that nine 
of the original 15 variants they identified (three nonsense, 
one splice site and five missense mutations) are likely to be 
pathogenic. This number may be an overestimate given that 
pathogenicity was determined by a single functional assay 
and other supporting investigations, such as segregation 
analyses, are not reported.
Clinical management of women without cancer 
with a mutation
The average age of breast cancer diagnosis for RECQL 
mutation carriers is reported in both initial publications and 
follow-up studies. Cybulski et al. report a mean age of diag-
nosis of 54.5 years in RECQL mutation carriers in the Polish 
population and 48.9 years in the Canadian population. In the 
German cohort analysed by Bogdanova et al. the mean age 
of diagnosis for RECQL mutation carriers was 51 years, and 
in the patients from Belarus the mean age of diagnosis was 
46 years. Sun et al. report a mean age of onset of breast can-
cer of 45.1 years in the patients in whom pathogenic RECQL 
mutations were identified (range 31–71 years), and on anal-
ysis of pedigrees of affected family members the average 
age of breast cancer diagnosis was 47.8 years. Kwong et al. 
report a mean age at diagnosis of 48.9 years in patients car-
rying a RECQL mutation. Carriers of the p.I156M missense 
variant identified by Tervasmäki et al. were diagnosed at a 
mean age of 60 years. In none of the analyses was there a 
statistically significant difference in age at diagnosis between 
RECQL mutation carriers and controls.
Testing for hereditary breast cancer genes is increasingly 
carried out using cancer gene panels. Deciding which genes 
and variants should be included on such panels is a subject 
of much debate [21–24]. When designing gene panels for 
routine clinical use, careful review of the data for each gene 
should be undertaken to determine whether the test result 
will be of clinical utility in the management of that patient 
and/or their family members. When counselling patients it 
is important that reliable information on relative or abso-
lute breast cancer risk can be provided, which will guide 
screening and management advice. For recently identified 
susceptibility genes, interpretation of results can prove prob-
lematic when novel variants are identified, particularly in 
ethnic groups in which there is minimal data on population 
variants, and little functional data is available. Against these 
limitations, the benefits of expanding such gene panels to 
include newly identified genes, which may provide valuable 
information on familial breast cancer cases, and would not 
previously have been identified, must be balanced. Overall, 
at present, the significant limitations in the available data 
on RECQL means that testing of RECQL outside a research 
setting should not be undertaken.
Clinical guidance for women in whom a putatively patho-
genic RECQL mutation is identified can only be based on 
limited data at present, and consideration of family history 
and other risk factors should form the major part of the clini-
cal assessment, including the level of breast surveillance to 
offer. The current contradictory evidence means that one 
cannot use RECQL mutation status to guide any aspect of 
clinical management such as breast surveillance or consid-
eration of risk reducing mastectomy. Although a family his-
tory of ovarian cancer is described in a small number of 
cases, studies to date have not identified any individuals with 
ovarian cancer who carry a RECQL mutation, and there is 
no evidence base on which to recommend ovarian cancer 
surveillance or prophylactic oophorectomy.
Conclusions
The initial evidence independently put forward by Cybulski 
and Sun proposed RECQL as a novel breast cancer suscep-
tibility gene responsible for a small proportion of hereditary 
breast cancer. The possibility of founder mutations in the 
Polish, French-Canadian and Chinese populations was pos-
tulated. Data from subsequent studies has provided further 
information on frequencies of RECQL variants in additional 
case – control cohorts. Much of this work does not support 
the association between increased breast cancer risk and loss 
of function RECQL mutations.
Variations in methodology, for example, the presence of 
sufficient matched controls and exclusion of certain vari-
ants, may account for some differences between studies. 
Variants detected at a low frequency in an affected patient 
group may be viewed as founder mutations, but if these are 
then found at a similar frequency in an unaffected control 
population, such claims need to be reviewed. The presence 
of potential loss of function RECQL variants at frequen-
cies > 0.01% in several ethnically distinct populations may 
indicate a number of founder mutations, each with a small 
but significant increased risk of breast cancer, or it may be 
evidence of a lack of association between variants in this 
gene and increased breast cancer risk. It is also possible 
that only certain RECQL variants are pathogenic or that that 
RECQL mutations are only pathogenic in combination with 
other susceptibility alleles. With the limited and conflict-
ing evidence available, there remains debate as to whether 
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there is an increased breast cancer risk for women carrying 
RECQL loss-of-function variants.
Further studies are required to better quantify the risks 
associated with RECQL variants. Widening research to a 
broader population base of hereditary breast cancer cohorts 
will help to improve the understanding of the global sig-
nificance of this gene. There are currently insufficient data 
to warrant inclusion of RECQL on hereditary breast cancer 
gene panels used in routine clinical practice. Management 
of patients in whom RECQL variants have been identified 
should be based on clinician assessment in the context of the 
family history, not RECQL mutation status.
As more data become available the importance of identi-
fying pathogenic RECQL mutations in women with a family 
history of breast cancer will become clearer. The impor-
tant role of RECQL in the DNA damage response raises 
the possibility that identification of RECQL mutations 
might have potential therapeutic implications for women 
with breast cancer. In vitro studies have demonstrated that 
RECQL-deficient cells are particularly sensitive to topoi-
somerase inhibition [18]. As in the case of tumours deficient 
in BRCA1/BRCA2, the deficient DNA repair in RECQL-defi-
cient tumours could increase their sensitivity to other drugs 
blocking compensatory DNA repair mechanisms [25]. Infor-
mation on genetic variants could help to identify populations 
of interest for trials of targeted therapeutics.
Given the conflicting data at present, it is inappropriate 
to recommend clinical guidelines on screening and manage-
ment. Further case–control studies in large and ethnically 
diverse populations are needed to better understand whether 
there is an increased risk of breast or other cancers associ-
ated with specific RECQL variants.
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